Table 1.

Characteristics of the whole cohort of 66 patients who had IgAN and were randomly assigned to receive benazepril 0.2 mg/kg per d (ACE-I group) or placeboa

CharacteristicACE-I Group(n = 32)Placebo Group(n = 34)
Age at randomization (yr; mean ± SD)21.8 ± 6.319.3 ± 6.1
Gender (male/female)24/824/10
CrCl (ml/min per 1.73 m2; mean ± SD)113.2 ± 23.5114.1 ± 19.0
eGFR (ml/min per 1.73 m2; mean ± SD)b116.0 ± 24.3109.2 ± 18.0
CrCl categories (ml/min per 1.73 m2; n [%])
    ≥90 (K/DOQI stage 1)26/32 (81)31/34 (91)
    60 to 89 (K/DOQI stage 2)6/32 (19)3/34 (9)
Proteinuria (g/d per 1.73 m2; mean ± SD)1.61 ± 0.701.87 ± 0.74
Proteinuria categories (g/d per 1.73 m2; n [%])
    between 1.0 and 1.518/32 (56)15/34 (44)
    between 1.5 and 2.510/32 (31)12/34 (35)
    between 2.5 and 3.54/32 (13)7/34 (21)
Mean BP (mmHg; mean ± SD)
    systolic122.59 ± 9.0117.06 ± 11.0
    diastolic77.81 ± 8.072.09 ± 9.0
ABPM: MAP (mmHg in adults)93.45 ± 8.094.7 ± 6.1
BP categories (n [%])c
    hypertension2/32 (6)3/34 (9)
    high-normal BP5/32 (16)3/34 (9)
    normotension25/32 (78)28/34 (82)
Follow-up (mo; median [range]), all 66 randomized patients35 (0 to 58)38 (3 to 53)
Follow-up (mo; median [range]), in 57 patients with follow-up >3 mo46.0 (14 to 58)38 (3 to 53)
  • a No significant difference was found between the ACE-I and the placebo groups. ABPM, ambulatory BP monitoring; ACE-I, angiotensin-converting enzyme inhibitor; CrCl, creatinine clearance; eGFR, estimated GFR; IgAN, IgA nephropathy; K/DOQI, Kidney Disease Outcomes Quality Initiative; MAP, mean arterial pressure.

  • b Calculated according to the Schwartz formula (21) for pediatric patients (≤18 yr of age) or Cockcroft formula (20) for adults.

  • c Hypertension was classified according to the international criteria in use when the IgACE trial was designed in 1995 to 1997. For adults, the sixth report of Joint Committee on high BP, 1997 (22), considered patients to be hypertensive with BP ≥140/90 mmHg, high normal with BP 130 to 139/85 to 89 mmHg, and normotensive with BP ≤129/85 mmHg. The Task Force for Hypertension in Children, 1996 (23) considered patients to be hypertensive with BP ≥95th centile for height and gender, high-normal with BP between 90th and 94th centiles, and normal with BP ≤90th centile.